Strong Q4 performance drives Baxter’s stock price up by 8%
Baxter (NYSE: BAX) saw a notable 8% increase in stock price, reaching $33.29 per share, following its better-than-expected fourth-quarter results for the year ending December 31, 2024.
Q4 Highlights:
- Revenue: $2.75 billion, a 1% YoY growth.
- Losses: $512 million or $1 per share from both continuing and discontinued operations.
- Adjusted EPS: 77¢, with continuing operations at 58¢ per share, beating Wall Street estimates by 6¢.
- Sales: Exceeded forecasts, driven by strong performance in the Medical Products & Therapies and Pharmaceuticals segments.
Key Factors Driving Results:
- Novum IQ Infusion Pump: A significant sales driver for the company.
- Hurricane Helene Impact: Sales in IV solutions were impacted by the hurricane but less than anticipated due to quick recovery efforts.
